CTAD 2019

The development of the next generation of Alzheimer's disease is one of the most important health needs worldwide. The goal of the meeting is to bring together today's worldwide leaders in the treatment of Alzheimer's disease, to discuss new results, and to develop therapeutic approaches.
Clinical trial teams from around the globe will report on their efforts to identify new and emerging risk factors.
The future of clinical trials may be new in their treatment of AD treatment. We know the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early in the disease process. We also learned more about another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.